ZIOPHARM Oncology, Inc. (ZIOPHARM) is a development-stage biopharmaceutical company. The Company focuses on developing and commercializing a portfolio of in-licensed cancer drugs that address unmet medical needs. The Company is focused on licensing and developing drug candidate families that are related to cancer therapeutics already on the market or in development and that can be developed in intravenous (IV) and/or oral forms of administration. As of December 31, 2008, it was in Phase I and Phase I/II studies for three product candidates known as darinaparsin (Zinapar ZIO-101), palifosfamide (Zymafos ZIO-201) and indibulin ( Zybulin ZIO-301).